<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/DCB77A98-C3FF-48BF-91D3-58D50258B11E" ns1:id="DCB77A98-C3FF-48BF-91D3-58D50258B11E"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/0B6971D8-89E1-4DEA-8E69-0E14B001C59D" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/0B6971D8-89E1-4DEA-8E69-0E14B001C59D" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2015-07-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/BEEECC50-FE84-41D0-9B1C-39428A10C160" ns1:rel="FUND" ns1:start="2015-02-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">751995</ns2:identifier></ns2:identifiers><ns2:title>Nanommune</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Vouchers</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Based in Cambridge, UK, Nanommune Biotech has a
core focus on the discovery and development of nanoscale combinatorial cancer immunotherapies.
Based on the unique properties of quantum-dot nanoparticles and immunostimulatory monoclonal
antibodies, Nanommune Biotech aims to develop artificial costimulatory cells that can trigger a highly
effective anti-tumour immune response as a result of a multi-layered co-stimulation of T-cells in cancer
patients. The voucher will be used in IP advisers</ns2:abstractText></ns2:project>